# The prognostic value of soluble ST2 in adults with pulmonary hypertension

#### Authors:


Laurie W. Geenen, BSc, Vivan J.M. Baggen, MD, PhD, Robert M. Kauling, MD, Thomas Koudstaal, MD, Karin A. Boomars, MD, PhD, Eric Boersma, MD, PhD, Jolien W. Roos-Hesselink, MD, PhD, Annemien E. van den Bosch, MD, PhD,

## SUPPLEMENTARY MATERIAL

### List of files


### Page

Supplementary File 1. Flowchart of the patient selection process	1
Supplementary File 2. Correlation between 2log transformed sST2 and NT-proBNP lewith pulmonary hypertension	
<b>Supplementary File 3</b> . Event-free survival according to the tertile distribution of sST2 with pulmonary hypertension	



**Supplementary File 1**. Patient selection process of the prospective observational study including adult patients with pulmonary hypertension.


**Abbreviations:** PH = pulmonary hypertension, RHC= right heart catheterization, sST2= soluble suppression of tumorigenicity-2, mPAP= mean pulmonary artery pressure, PAH= pulmonary arterial hypertension, iPAH= idiopathic pulmonary arterial hypertension, PVOD= pulmonary veno-occlusive disease, CTEPH= chronic thromboembolic pulmonary hypertension, WHO5= world health organization class 5.



**Supplementary File 2.** Correlation between 2log transformed sST2 and NT-proBNP levels in adults with pulmonary hypertension.

Spearman correlation coefficient: r=0.54, p=0.001

**Abbreviations**: sST2= soluble suppression of tumorigenicity-2, NT-proBNP= N-terminal pro-B type natriuretic peptide.



**Supplementary File 3.** Event-free survival according to the tertile distribution of sST2 in adults with pulmonary hypertension.

**Legend:** T1 = first tertile, T2 = second tertile, T3 = third tertile. The percentage shows the cumulative end-point free survival at 6 years of follow-up according to each tertile of the sST2 distribution.